
|Articles|January 28, 2010
supplement promo
In this January 2010 supplement to Oncology, guest editor Axel Grothey from the Mayo Clinic, explores adjuvant therapy considerations in stage II colon cancer.
Advertisement
In this January 2010 supplement to Oncology, guest editor Axel Grothey from the Mayo Clinic, explores adjuvant therapy considerations in stage II colon cancer.
This supplement and associated publication costs were funded by Genomic Health.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Related Content
Advertisement

ByPedram Razavi,Joyce O’Shaughnessy, MD,Lasika Seneviratne, MD,Mehnaj Ahmed,Ashley Roush,Siddhi Korgaonkar,Abigail Hitchens,Keith L. Davis,Anton Safonov,Mark Robson, MD,Yanjun Ma,Brittni Smith,Lorraine Brisbin,Siraje Mahmud,Laura Ensley,Robert Milford,Elan Ingram,Vaidyanathan Ganapathy,Corinth Auld,Mumbi E. Kimani,Liz Santarsiero,L. Johnetta Blakely, MD




Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Novel HP1K Inhibitor Shows Favorable Responses in ccRCC, Solid Tumors
2
MYTHIC Trial Demonstrates Efficacy in Platinum-Resistant Ovarian Cancer
3
FDA Grants RMAT Designation to RZ-001 in Advanced Hepatocellular Carcinoma
4
119 Progression-Free Survival (PFS) and Overall Survival (OS) Results From the Phase 3 MONALEESA-3 Trial of Postmenopausal Patients With Hormone Receptor–Positive (HR+)/Human Epidermal Growth Factor Receptor 2–Negative (HER2−) Advanced Breast Cancer (ABC) Treated With Ribociclib (RIB) + Fulvestrant (FUL): A Subgroup Analysis of Patients With Invasive Lobular Carcinoma (ILC)
5

















































